US 12,390,459 B2
Methods for solid tumor treatment
Mike Baltezor, Lawrence, KS (US); Gere diZerega, Lawrence, KS (US); Charles Decedue, Lawrence, KS (US); Sam Campbell, Lawrence, KS (US); and Matt McClorey, Lawrence, KS (US)
Assigned to CRITITECH, INC., Lawrence, KS (US)
Filed by CRITITECH, INC., Lawrence, KS (US)
Filed on Sep. 12, 2022, as Appl. No. 17/931,468.
Application 17/931,468 is a continuation of application No. 16/839,737, filed on Apr. 3, 2020, granted, now 11,458,133.
Application 16/839,737 is a continuation of application No. 16/512,044, filed on Jul. 15, 2019, granted, now 11,033,542, issued on Jun. 15, 2021.
Application 16/512,044 is a continuation of application No. 16/136,502, filed on Sep. 20, 2018, granted, now 10,391,090, issued on Aug. 27, 2019.
Application 16/136,502 is a continuation of application No. PCT/US2017/025718, filed on Apr. 3, 2017.
Claims priority of provisional application 62/378,543, filed on Aug. 23, 2016.
Claims priority of provisional application 62/318,014, filed on Apr. 4, 2016.
Prior Publication US 2023/0172927 A1, Jun. 8, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/10 (2006.01); A61K 9/14 (2006.01); A61K 9/19 (2006.01); A61K 31/337 (2006.01); A61K 31/4439 (2006.01); A61K 31/4745 (2006.01); A61K 31/475 (2006.01); A61K 31/513 (2006.01); A61K 31/555 (2006.01); A61K 31/704 (2006.01); A61K 31/7048 (2006.01); A61K 31/7068 (2006.01); A61K 33/243 (2019.01); A61K 47/26 (2006.01); A61K 47/10 (2017.01)
CPC A61K 31/475 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 9/10 (2013.01); A61K 9/14 (2013.01); A61K 31/337 (2013.01); A61K 31/4439 (2013.01); A61K 31/4745 (2013.01); A61K 31/513 (2013.01); A61K 31/555 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 31/7068 (2013.01); A61K 33/243 (2019.01); A61K 47/26 (2013.01); A61P 35/00 (2018.01); A61K 47/10 (2013.01)] 20 Claims
 
1. A method for treating a solid tumor, comprising administering to a subject with a solid tumor an amount effective of a composition comprising taxane particles to treat the tumor, wherein the composition is directly injected into the tumor, wherein the taxane particles comprise at least 95% taxane or a pharmaceutically acceptable salt thereof, wherein the taxane particles have a specific surface area (SSA) of at least 18 m2/g, and wherein the solid tumor is an adenocarcinoma.